An Antioxidants-rich Nutraceutical Product from Haskap Berry

Avive Naturals Inc .位于新斯科舍省贝德福德（www.avive.ca），是cGMP认证工厂，自2010年以来获得加拿大卫生部批准和许可生产天然保健产品（NHP）。为了满足日益增长的消费者需求，该公司希望生产和销售从加拿大新兴的“超级食品”haskap浆果中提取的富含膳食抗氧化剂的胶囊。然而，该公司面临的挑战是，按照加拿大卫生部的要求，生产具有最终产品中抗氧化剂含量一致性的anNHP。山楂的主要抗氧化活性物质是花青素，其含量因不同品种的采收成熟度以及加工和储存过程中的降解程度而有很大差异。该项目将建立采收成熟度指标，以确定该新引进浆果机械采收的最佳生物活性含量。为了在生产过程中最大限度地保留花青素，还将确定预处理和干燥方法。了解储存过程中光线的影响将有助于公司决定最终产品所需的包装类型。最终产品的花青素含量和抗氧化剂含量的表征将为公司计算新NHP的推荐剂量提供依据。除了预期的花青素含量和抗氧化声明外，拟议的研究还将探索推荐这种NHP产品用于2型糖尿病治疗的潜力。这种新的行业合作伙伴关系不仅将直接帮助公司开发新的nhp，而且还将在加拿大推广高价值的经济作物。此外，新的NHP还将有助于管理因慢性氧化应激相关疾病而日益增长的加拿大医疗负担。

Avive Naturals Inc of Bedford, Nova Scotia (www.avive.ca) is cGMP certified facility approved and licensedby Health Canada to manufacture Natural Health Products (NHP) since 2010. To meet the growing consumerdemand, the company wish to manufacture and market dietary antioxidants-rich capsule derived from thehaskap berry, an emerging "superfood" in Canada. However, the company is challenged to manufacture anNHP with the consistency of the antioxidant content in the final product as required by Health Canada. Themajor antioxidant bioactives of haskap are anthocyanin's, which highly differ due to harvest maturity ofcultivars as well as subjected to degradation during processing and storage. The proposed project will establishharvest maturity indices to decide the optimum bioactive content for mechanical harvesting of this newlyintroduced berry. Pre-treatments and drying methods will also be identified for maximum retention ofanthocyanins during the manufacturing. Understanding the impact of light during storage will help thecompany to decide the type of packaging required for the final product. The characterization of anthocyanincontent and antioxidant content of the final product will provide the company a basis for calculating therecommended dose of the new NHP. In addition to the intended anthocyanin content and antioxidant claim, theproposed research will also explore the potential of recommending this NHP product for the management oftype 2 diabetes. This new industry partnership will directly help not only the company to develop a new NHPbut also to promote a high-value cash crop in Canada. Moreover, the new NHP will also contribute tomanaging the growing Canadian healthcare burden due to chronic oxidative stress-associated disorders.